Nature Structural & Molecular Biology, Год журнала: 2022, Номер 29(10), С. 978 - 989
Опубликована: Окт. 1, 2022
Язык: Английский
Cell, Год журнала: 2019, Номер 179(1), С. 236 - 250.e18
Опубликована: Сен. 1, 2019
Язык: Английский
Процитировано
263
World Journal of Biological Chemistry, Год журнала: 2021, Номер 12(5), С. 57 - 69
Опубликована: Сен. 22, 2021
Proteomics is the complete evaluation of function and structure proteins to understand an organism's nature.Mass spectrometry essential tool that used for profiling in cell.However, biomarker discovery remains major challenge proteomics because their complexity dynamicity.Therefore, combining approach with genomics bioinformatics will provide understanding information biological systems disease alteration.However, most studies have investigated a small part blood.This review highlights types proteomics, available proteomic techniques, applica-tions different research fields.
Язык: Английский
Процитировано
196
Laboratory Investigation, Год журнала: 2022, Номер 102(11), С. 1170 - 1181
Опубликована: Авг. 3, 2022
Язык: Английский
Процитировано
182
Molecular Systems Biology, Год журнала: 2019, Номер 15(12)
Опубликована: Дек. 1, 2019
Recent developments in proteomics have enabled signaling studies where > 10,000 phosphosites can be routinely identified and quantified. Yet, current analyses are limited throughput, reproducibility, robustness, hampering experiments that involve multiple perturbations, such as those needed to map kinase-substrate relationships, capture pathway crosstalks, network inference analysis. To address these challenges, we introduce rapid-robotic phosphoproteomics (R2-P2), an end-to-end automated method uses magnetic particles process protein extracts deliver mass spectrometry-ready phosphopeptides. R2-P2 is rapid, robust, versatile, high-throughput. showcase the method, applied it, combination with data-independent acquisition spectrometry, study dynamics mitogen-activated kinase (MAPK) yeast. Our results reveal broad specific events along mating, high-osmolarity glycerol, invasive growth branches of MAPK pathway, robust phosphorylation downstream regulatory proteins transcription factors. facilitates large-scale involving hundreds perturbations opening door systems-level aiming complexity.
Язык: Английский
Процитировано
154
Molecular Cancer, Год журнала: 2022, Номер 21(1)
Опубликована: Фев. 15, 2022
Alterations in DNAs could not reveal what happened proteins. The accumulated alterations of would change the manifestation Therefore, as is case cancer liquid biopsies, deep proteome profiling will likely provide invaluable and clinically relevant information real-time throughout all stages progression. However, due to great complexity proteomes biopsy samples limitations proteomic technologies compared high-plex sequencing technologies, discoveries have yet lagged behind their counterpart, genomic technologies. novel protein are urgent demand fulfill goals set out for biomarker discovery biopsies.Notably, conventional innovative being rapidly developed analysis biopsies. These advances greatly facilitated early detection, diagnosis, prognosis, monitoring evolution, adapted or adopted response therapeutic interventions. In this paper, we review proteomics that capable measuring at least hundreds proteins simultaneously from samples, ranging traditional based on mass spectrometry (MS) antibody/antigen arrays aptamer, proximity extension assay (PEA), reverse phase (RPPA).
Язык: Английский
Процитировано
147
Molecules, Год журнала: 2022, Номер 27(8), С. 2411 - 2411
Опубликована: Апрель 8, 2022
Mass Spectrometry (MS) allows the analysis of proteins and peptides through a variety methods, such as Electrospray Ionization-Mass (ESI-MS) or Matrix-Assisted Laser Desorption (MALDI-MS). These methods allow identification mass protein peptide intact molecules peptide-mass fingerprinting generated upon enzymatic digestion. Tandem spectrometry (MS/MS) fragmentation to determine amino acid sequence (top-down middle-down proteomics) (bottom-up proteomics). Furthermore, tandem also post-translational modifications (PTMs) peptides. Here, we discuss application MS/MS in biomedical research, indicating specific examples for their PTMs relevant biomarkers diagnostic therapy.
Язык: Английский
Процитировано
71
Cancers, Год журнала: 2023, Номер 15(5), С. 1579 - 1579
Опубликована: Март 3, 2023
Cancer is among the leading causes of death worldwide. Early diagnosis and prognosis are vital to improve patients’ outcomes. The gold standard tumor characterization tissue biopsy. Amongst constraints biopsy collection sampling frequency incomplete representation entire bulk. Liquid approaches, including analysis circulating cells (CTCs), DNA (ctDNA), miRNAs, tumor-derived extracellular vesicles (EVs), as well certain protein signatures that released in circulation from primary tumors their metastatic sites, present a promising more potent candidate for patient follow up monitoring. minimally invasive nature liquid biopsies, allowing frequent collection, can be used monitoring therapy response real time, development novel approaches therapeutic management cancer patients. In this review we will describe recent advances field markers focusing on advantages disadvantages.
Язык: Английский
Процитировано
70
Clinical Proteomics, Год журнала: 2023, Номер 20(1)
Опубликована: Авг. 26, 2023
Abstract Mass spectrometry (MS)-based proteomics have been increasingly implemented in various disciplines of laboratory medicine to identify and quantify biomolecules a variety biological specimens. MS-based is continuously expanding widely applied biomarker discovery for early detection, prognosis markers treatment response prediction monitoring. Furthermore, making these advanced tests more accessible affordable will the greatest healthcare benefit. This review article highlights new paradigms clinical has created microbiology laboratories, cancer research diagnosis metabolic disorders. The technique preferred over conventional methods disease detection therapy monitoring its combined advantages multiplexing capacity, remarkable analytical specificity sensitivity low turnaround time. Despite achievements development adoption number practices, are expected undergo transition from bench bedside near future. provides insights trials recent progresses (mainly covering literature NCBI database) application laboratories.
Язык: Английский
Процитировано
63
Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)
Опубликована: Март 22, 2024
Abstract Cancer early detection and treatment response prediction continue to pose significant challenges. liquid biopsies focusing on detecting circulating tumor cells (CTCs) DNA (ctDNA) have shown enormous potential due their non-invasive nature the implications in precision cancer management. Recently, biopsy has been further expanded profile glycoproteins, which are products of post-translational modifications proteins play key roles both normal pathological processes, including cancers. The advancements chemical mass spectrometry-based technologies artificial intelligence-based platforms enabled extensive studies organ-specific changes glycans glycoproteins through glycomics glycoproteomics. Glycoproteomic analysis emerged as a promising tool for biomarker discovery development cancers efficacy immunotherapies. These biomarkers could crucial role aiding intervention personalized therapy decisions. In this review, we summarize advance glycoproteomic promise challenges integration into clinical practice improve patient care.
Язык: Английский
Процитировано
23
Clinical Proteomics, Год журнала: 2024, Номер 21(1)
Опубликована: Янв. 30, 2024
Routine measurement of cancer biomarkers is performed for early detection, risk classification, and treatment monitoring, among other applications, has substantially contributed to better clinical outcomes patients. However, there remains an unmet need clinically validated assays protein biomarkers. Protein tumor markers are particular interest since proteins carry out the majority biological processes thus dynamically reflect changes in pathophysiology. Mass spectrometry-based targeted proteomics a powerful tool absolute peptide quantification matrices with numerous advantages that make it attractive applications oncology. The use liquid chromatography-tandem mass spectrometry (LC-MS/MS) based methodologies allowed laboratories overcome challenges associated immunoassays more widely used marker measurements. Yet, implementation so far been limited few markers. This due paucity robust validation studies new labor-intensive operationally complex nature LC-MS/MS workflows. purpose this review provide overview cancer, workflows proteomics, requirements assays. We will also discuss MS-based biomarker analysis highlight some recent developments positively contribute technique into laboratories.
Язык: Английский
Процитировано
18